1. Home
  2. INBX vs VALN Comparison

INBX vs VALN Comparison

Compare INBX & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inhibrx Inc.

INBX

Inhibrx Inc.

HOLD

Current Price

$61.49

Market Cap

999.7M

Sector

Health Care

ML Signal

HOLD

Logo Valneva SE

VALN

Valneva SE

HOLD

Current Price

$6.25

Market Cap

875.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INBX
VALN
Founded
2010
2012
Country
United States
France
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
999.7M
875.7M
IPO Year
2024
2021

Fundamental Metrics

Financial Performance
Metric
INBX
VALN
Price
$61.49
$6.25
Analyst Decision
Hold
Strong Buy
Analyst Count
2
4
Target Price
N/A
$15.75
AVG Volume (30 Days)
155.9K
86.6K
Earning Date
03-19-2026
03-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,300,000.00
N/A
Revenue This Year
N/A
$4.00
Revenue Next Year
N/A
$92.04
P/E Ratio
N/A
N/A
Revenue Growth
550.00
N/A
52 Week Low
$10.81
$5.43
52 Week High
$94.57
$12.25

Technical Indicators

Market Signals
Indicator
INBX
VALN
Relative Strength Index (RSI) 37.65 25.15
Support Level $28.54 $5.69
Resistance Level $85.97 $6.73
Average True Range (ATR) 4.28 0.40
MACD -0.55 -0.53
Stochastic Oscillator 21.52 0.84

Price Performance

Historical Comparison
INBX
VALN

About INBX Inhibrx Inc.

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

About VALN Valneva SE

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

Share on Social Networks: